Articles tagged with: pre-exposure prophylaxis (PrEP)

What I've learned through training

published: October, 13, 2017 Written by // Megan DePutter Categories // Social Media, As Prevention , Gay Men, General Health, Treatment Guidelines -including when to start, Women, Health, International , Treatment, Living with HIV, Media, Megan DePutter, Opinion Pieces

Megan DePutter reflects on some of the high points as she prepares to go on maternity leave.

What I've learned through training

I’ve spent the last 1.5 years delivering training on HIV and related topics in Scotland. The audience has been diverse – it’s included nurses, GP’s, infant feeding advisors, midwives, therapists, social workers, addictions and criminal justice workers, dieticians and occupational therapists, psychologists, early childcare workers, people who work with vulnerable adults, students and people in a wide variety of other roles! During this period I’ve delivered training for nearly 550 peo

Many gay/bisexual men currently taking PrEP would switch to injectable forms of the therapy should it become available

published: October, 12, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, African, Caribbean and Black, As Prevention , Gay Men, Treatment Guidelines -including when to start, Research, Sexual Health, Health, Revolving Door, International , Treatment, Guest Authors, Media

"It removes the requirement to take daily treatment and the need to maintain high levels of treatment adherence." From AIDSmap, Michael Carter reports.

Many gay/bisexual men currently taking PrEP would switch to injectable forms of the therapy should it become available

Approximately a third of gay and bisexual men who are currently taking oral (tenofovir/emtricitabine) pre-exposure prophylaxis (PrEP) would prefer long-acting injectable PrEP should it become available, investigators report in AIDS and Behavior. Individuals were less likely to prefer injectable PrEP if they had concerns about the level of protection it provided against HIV and/or about its durability. “About one-third of GBM [gay and bisexual men] currently taking oral PrEP would prefer LA

U.S. simulation explores the intersection of PrEP and some sexually transmitted infections

published: October, 10, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , Gay Men, CATIE, General Health, Treatment Guidelines -including when to start, Research, Health, Sexual Health, CATIE - HIV and Hep C Info Resource, Treatment, Lifestyle, Media

"The results of the researchers’ simulations show that PrEP should be considered as a package of interventions, of which STI screening and treatment are an important part. From Catie, Sean R. Hosein reports.

U.S. simulation explores the intersection of PrEP and some sexually transmitted infections

The use of medicines to prevent a person from becoming infected with HIV is called pre-exposure prophylaxis (PrEP). PrEP consists of two anti-HIV drugs—tenofovir DF and FTC—in one pill. In clinical trials with gay, bisexual and other men who have sex with men (MSM), PrEP has been highly effective in preventing the spread of HIV. According to a team of U.S. researchers who analysed data from several clinical trials, the consistent use of PrEP can reduce the risk of HIV infection “by more

Psychological impact of PrEP: beyond efficacy and cost-effectiveness

published: October, 09, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, As Prevention , Gay Men, Treatment Guidelines -including when to start, Mental Health, Revolving Door, International , Treatment, Guest Authors, Media

What is the impact of PrEP on quality of life? From HIV i-Base, Simon Collins reports

Psychological impact of PrEP: beyond efficacy and cost-effectiveness

The impact of PrEP on quality of life in reducing HIV-related anxiety and more dynamic and fulfilled sex lives is potentially as important as hard endpoints for reduced HIV infections. Mitzy Gafos presented experiences from using PrEP as part of the UK PROUD study, based on semi-structured interviews with 41 participants. In addition to reporting behavioural changes, the results gave insight into psychological impact of PrEP. Many of these imply significant changes in outlooks and approach

Amsterdam PrEP failure patient had unusual course of HIV infection

published: October, 04, 2017 Written by // Guest Authors - Revolving Door Categories // Guest Authors

Researchers speculate that continued PrEP might stop local infections becoming systemic. From AIDSmap, Gus Cairns reports.

Amsterdam PrEP failure patient had unusual course of HIV infection

At last February’s Conference on Retroviruses and Opportunistic Infections (CROI), Dutch clinicians presented a so-far unique case of a man who had apparently become infected with non-drug-resistant HIV while taking pre-exposure prophylaxis (PrEP) consistently. Two previous cases of PrEP failure had been reported, but in both cases, the men concerned had been infected with multidrug-resistant HIV. This case, therefore, raised concerns that PrEP may not be 100% effective. The case has

Ontario to cover HIV prevention pill under public health plan

published: September, 22, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, Activism, As Prevention , Current Affairs, General Health, Treatment Guidelines -including when to start, Health, Revolving Door, Treatment, Guest Authors, Media

Once-daily pill contains two anti-HIV drugs that reduce the risk of sexual transmission of virus

Ontario to cover HIV prevention pill under public health plan

Generic versions of pre-exposure prophylaxis or PrEP to prevent HIV are becoming more available in Canada. (CBC) To read the complete article, visit CBC News, here. Ontario will soon cover a combination HIV prevention pill that is now available in generic form, HIV advocates say. The once-daily pill contains two anti-HIV drugs that reduce the risk of sexual transmission in HIV-negative individuals. Pre-exposure prophylaxis, or PrEP, originally cost about $1,000 a month as the brand nam

GIPA takes a hit

published: September, 20, 2017 Written by // Bob Leahy - Publisher Categories // Activism, featured, Social Media, As Prevention , Current Affairs, General Health, Treatment Guidelines -including when to start, Health, Treatment, Living with HIV, Media, Opinion Pieces, Bob Leahy - Publisher

As funding starts to slow, engagement and involvement of people living with HIV is often the first to go. Bob Leahy on the politics of inclusion, exclusion and how people living with HIV are fighting back

GIPA takes a hit

“It was the best of times; it was the worst of times: said Charles Dickens. “It was the age of wisdom, it was the age of foolishness, it was the epoch of belief, it was the epoch of incredulity." That was about Paris in 1869. It could have been written about Canada in 2017 and the state of our response to HIV. The best of times? Many feel we are approaching the end of the epidemic with 2030 set as the target date by UNAIDS. We are closing in on 90-90-90 targets which means more people li

New US PrEP cost-effectiveness model finds drug prices will need to drop substantially if HIV risk rises, or if adherence is only moderate

published: September, 19, 2017 Written by // Guest Authors - Revolving Door Categories // African, Caribbean and Black, Social Media, As Prevention , Gay Men, Youth, Treatment Guidelines -including when to start, Women, Revolving Door, International , Treatment, Guest Authors, Media

"With high adherence, PrEP saves money in high-prevalence populations even at current costs." From AIDSmap, Gus Cairns reports.

New US PrEP cost-effectiveness model finds drug prices will need to drop substantially if HIV risk rises, or if adherence is only moderate

A new US model of the cost-effectiveness of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM), prepared by researchers at Emory University in Atlanta, finds that taking even one year of PrEP is more cost-effective than measures like kidney dialysis, if it is used by people belonging to populations where HIV prevalence is at least 10%. However, for PrEP to actually save money, relative to the lifetime cost of treating the HIV infections that would otherwise happen, either

Kenya at the forefront in tackling HIV

published: September, 13, 2017 Written by // Kimutai Kemboi, Categories // African, Caribbean and Black, Social Media, Activism, Kimutai Kemboi, As Prevention , Youth, General Health, Treatment Guidelines -including when to start, Health, International , Treatment, Living with HIV, Media, Opinion Pieces

From Kenya, HIV activist and stigma fighter Kimutai Kemboi on the initiatives the Kenyan government has taken together with other stakeholders in the struggle against HIV.

Kenya at the forefront in tackling HIV

Kenya, as a developing country, is among the African countries on the forefront in tackling HIV as well as investing personnel and resources. The government and the stake holders have done a lot though more needs to be done. The Kenyan government has given a favourable environment to stakeholders who wish to partake in this battle. Many organizations have set up facilities that offer HIV related services to people from the marginalised classes of life such as rural and slum populations. The s

No ordinary affair. IAS 2017 report from Paris, Part One: Conference highlights

published: August, 01, 2017 Written by // Bob Leahy - Publisher Categories // International AIDS Conference , Activism, Living with HIV, Bob Leahy - Publisher

Bob Leahy was in Paris last week covering the big IAS conference on HIV Science. Turns out it was the best he had been to and not just because Undetectable=Untransmittable (U=U) almost stole the show. Here is what else happened.

No ordinary affair. IAS 2017 report from Paris, Part One: Conference highlights

International AIDS Society Conferences come in two sizes. They alternate. Next year will be the big one in Amsterdam which deals with the whole panoply of HIV knowledge, including science and research and more. It will likely attract about 20,000 people. This year’s alternate year conference was just about HIV science, a smaller affair with 8,000 or so of us in attendance from 40 countries with an agenda less community-based. In other words, it was potentially a bit dull. This one certainl

[12 3 4 5  >>